JAK1 and psoriasis: Apart from neutralizing antibodies, such as those against IL-17 or IL-23, various STAT3 signaling pathway inhibitors, such as Tofacitinib, an oral JAK1/3 inhibitor [22], or Ruxolitinib, a topically applied JAK1/2 inhibitor that could block STAT3 phosphorylation, have been approved for clinical trials for the treatment of psoriasis [23, 24].